CD68 and cancer: In summary, considering the limitations of having analyzed small cohorts from these five solid tumor indications, the presented PD‐L1, TIL, and CD68 IHC data constitute the first quantitative screen using IHC DIA in pediatric oncology, proposing that the immunophenotype of the pediatric indications analyzed may not validate the PD‐L1 IHC biomarker patient selection strategy used for anti‐PD‐1/PD‐L1 monotherapies in adult cancer, while recommending focusing on other pediatric cancer groups.